EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Prognostic Impact of Brain Radiotherapy and Lactate Dehydrogenase in Melanoma with Brain Metastases: A Retrospective Cohort Study

Huishan Zhang, Mengru Quan, Zhongqiao Lin, Zequn Sun, Yu Chen, Jing Lin

Cancers · 09.05.2026 · 18 (10) · 1524

DOI: 10.3390/cancers18101524 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancers, online erschienen am 09.05.2026. Verfasst von Huishan Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Phase I Clinical Trial, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Startup Fund for scientific research, Fujian Provincial Health Commission Science and Technology, Joint Funds for the Innovation of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The prognosis of patients with advanced melanoma remains poor, particularly in those with brain metastases. To date, no standardized later-line treatment regimen has been established for this patient population. This study aimed to explore prognostic factors in patients with advanced melanoma and brain metastases, with a specific focus on the prognostic significance of baseline lactate dehydrogenase (LDH) levels and cranial radiotherapy. Materials and Methods: This retrospective cohort study consecutively enrolled 145 patients diagnosed with melanoma brain metastases (MBM) between 1 December 2015 and 31 August 2024. Baseline LDH data were available for 139 patients (95.9%), while the remaining six cases were excluded from LDH-stratified analyses. Patients were divided into an elevated LDH group (>250 U/L) and a normal LDH group (≤250 U/L). Collected clinical variables included brain intensity-modulated radiotherapy (IMRT), systemic treatment strategies (immunotherapy, targeted therapy, and chemotherapy), the number of prior treatment lines, and neurological symptoms at diagnosis. The completeness of all other clinical variables reached 100%. Univariate and multivariate Cox regression analyses were performed to identify independent prognostic factors for overall survival (OS) and progression-free survival (PFS). All statistical analyses were conducted using SPSS 21.0.

Results

The median OS of the entire cohort was 6.7 months (range: 0.4–101.0 months). Multivariate Cox regression identified three independent protective factors for superior OS and PFS: brain IMRT administration (OS: HR = 0.565, 95% CI: 0.365–0.874, p = 0.010; PFS: HR = 0.623, 95% CI: 0.420–0.924, p = 0.019), normal baseline LDH (OS: HR = 2.091, 95% CI: 1.425–3.069, p < 0.001; PFS: HR = 1.456, 95% CI: 1.023–2.071, p = 0.037), and ≤3 prior lines of systemic therapy before MBM diagnosis (OS: HR = 0.853, p = 0.004; PFS: HR = 1.679, p = 0.015). Moreover, the absence of neurological symptoms at baseline was an independent favorable prognostic factor for OS (HR = 1.919, p = 0.001) but not for PFS. Patients with normal LDH combined with brain IMRT exhibited the best OS and PFS outcomes (p < 0.001).

Conclusions

Baseline LDH level and cranial radiotherapy are robust independent prognostic indicators for survival in MBM patients. More prior treatment lines and the presence of neurological symptoms correlate with inferior clinical outcomes. These findings provide evidence for clinical risk stratification and individualized treatment decision-making for this high-risk and challenging population.

Schlagwörter

Stichwörter der Autor:innen

brain metastaseslactate dehydrogenase (LDH)melanomaoverall survivalprognosisradiotherapy

Autor:innen und Institutionen

  • Department of Phase I Clinical Trial, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
  • NHC Key Laboratory of Cancer Metabolism, Fujian Cancer Hospital, Fuzhou 350014, China.
  • College of Chemistry, Fuzhou University, Fuzhou 350014, China.
  • Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
  • Cancer Bio-Immunotherapy Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.

Förderung

  • Startup Fund for scientific research
  • Fujian Provincial Health Commission Science and Technology
  • Joint Funds for the Innovation of Science and Technology
  • Natural Science Foundation of Fujian Province
  • the Science Foundation for The Excellent Youth Scholars of Fujian Provincial Health Commission
  • Special Research Funds for Local Science and Technology Development Guided by Central Government
  • Joint Funds for the innovation of science and Technology, Fujian province
  • Fujian Provincial Health Science and Technology Program

Zitieren

APA

Zhang, H., Quan, M., Lin, Z., Sun, Z., Chen, Y., & Lin, J. (2026). Prognostic Impact of Brain Radiotherapy and Lactate Dehydrogenase in Melanoma with Brain Metastases: A Retrospective Cohort Study. Cancers, 18(10), 1524. https://doi.org/10.3390/cancers18101524

Vancouver

Zhang H, Quan M, Lin Z, Sun Z, Chen Y, Lin J. Prognostic Impact of Brain Radiotherapy and Lactate Dehydrogenase in Melanoma with Brain Metastases: A Retrospective Cohort Study. Cancers. 2026;18(10):1524. doi:10.3390/cancers18101524

BibTeX
@article{Zhang2026,
  author = {Zhang, Huishan and Quan, Mengru and Lin, Zhongqiao and Sun, Zequn and Chen, Yu and Lin, Jing},
  title = {Prognostic Impact of Brain Radiotherapy and Lactate Dehydrogenase in Melanoma with Brain Metastases: A Retrospective Cohort Study},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {10},
  pages = {1524},
  doi = {10.3390/cancers18101524}
}
Kostenlos starten →